Signals
8Thyroid cancer targeted therapy expands across differentiated, medullary, and anaplastic subtypes
RET inhibitor maturity, NTRK fusion-targeted use, BRAF V600E and MEK combinations in anaplastic disease, and emerging mechanism programs are restructuring thyroid cancer therapy.
Cholangiocarcinoma targeted therapy widens past chemotherapy
FGFR2 inhibitor maturity, IDH1 inhibitor use, HER2-targeted therapy entry, and IO combinations are restructuring biliary tract cancer management.
Glioblastoma therapy options evolve past temozolomide and TTFields
Tumour-treating fields maturity, IDH-mutant glioma vorasidenib approval, and emerging mechanism-targeted programs are reshaping glioma management.
Hepatocellular carcinoma systemic therapy options mature
Atezolizumab plus bevacizumab maturity, durvalumab plus tremelimumab adoption, and TIGIT-class programs are restructuring advanced HCC.
Tumor-infiltrating lymphocyte therapy expands past melanoma
TIL therapy approval in metastatic melanoma is opening pathways into cervical and other solid tumour indications.
PROTAC oncology pipeline is transitioning from concept to commercial reality
Targeted protein degradation programs (PROTACs and molecular glues) in oncology have moved from early-stage proof-of-concept to multiple late-stage assets with pivotal readouts in the next 24 months. The mechanism's promise of drugging previously undruggable targets is closer to commercial validation than at any prior point.
FDA accelerated-approval reform is changing oncology evidence requirements
Post-Aduhelm reform of the accelerated-approval pathway has tightened expectations for confirmatory trial design, enrolment timing, and surrogate-endpoint validity. Oncology programs targeting accelerated approval are seeing the practical effect first.
Antibody-drug conjugates are reshaping the HER2-low breast cancer setting
T-DXd's expansion into HER2-low has changed second-line decision-making, and the ADC class is delivering further candidates that are likely to redefine biomarker-driven sequencing across breast cancer subtypes.
Explained
2How combination regimens are restructuring late-line oncology trial design
Late-line oncology trials are increasingly testing combination regimens rather than single-agent comparisons. The trial-design conventions, the regulatory framework, and the commercial implications of combination-as-standard are different enough from single-agent design that cross-functional teams need to understand the shift.
How to read a modern phase 3 oncology readout: hazard ratios, crossover and what regulators care about
Phase 3 oncology trial readouts have a vocabulary, a set of conventions, and a regulatory frame that the headline numbers obscure. This is a plain-language guide to the parts of the readout that decide approval, label and reimbursement.